Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?

Zacks08-09

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458518289?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","is_english":true,"pubTime":"2024-08-09 21:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2458518289","market":"us","top_or_hot":-1,"title":"Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?","media":"Zacks","content":"<div>\n<p>The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mannkind-mnkd-stock-outpacing-medical-134012956.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-09 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mannkind-mnkd-stock-outpacing-medical-134012956.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mannkind-mnkd-stock-outpacing-medical-134012956.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/mannkind-mnkd-stock-outpacing-medical-134012956.html","article_id":"2458518289","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458518289","pubTimestamp":1723210812,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.MannKind is a member of our Medical group, which includes 1021 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.Adagene Inc. Sponsored ADR  is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27.9%.Adagene Inc. Sponsored ADR  : Free Stock Analysis Report","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗","BK4139":"生物科技","BK4584":"避孕概念","ADAG":"天演药业"},"translate_title":"MannKind(MNKD)股价今年是否超过医疗同行？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAG":1,"MNKD":1},"content_text":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.\nMannKind is a member of our Medical group, which includes 1021 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.\nThe Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MannKind is currently sporting a Zacks Rank of #1 (Strong Buy).\nThe Zacks Consensus Estimate for MNKD's full-year earnings has moved 6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.\nAccording to our latest data, MNKD has moved about 42.6% on a year-to-date basis. In comparison, Medical companies have returned an average of 6.6%. This shows that MannKind is outperforming its peers so far this year.\nAdagene Inc. Sponsored ADR (ADAG) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27.9%.\nOver the past three months, Adagene Inc. Sponsored ADR's consensus EPS estimate for the current year has increased 24.4%. The stock currently has a Zacks Rank #2 (Buy).\nLooking more specifically, MannKind belongs to the Medical - Biomedical and Genetics industry, which includes 499 individual stocks and currently sits at #75 in the Zacks Industry Rank. On average, stocks in this group have lost 1.6% this year, meaning that MNKD is performing better in terms of year-to-date returns. Adagene Inc. Sponsored ADR is also part of the same industry.\nGoing forward, investors interested in Medical stocks should continue to pay close attention to MannKind and Adagene Inc. Sponsored ADR as they could maintain their solid performance.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMannKind Corporation (MNKD) : Free Stock Analysis Report\nAdagene Inc. Sponsored ADR (ADAG) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458518289"}